These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 18833000

  • 1. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH.
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [Abstract] [Full Text] [Related]

  • 2. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
    Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A, Fey GH.
    J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
    [Abstract] [Full Text] [Related]

  • 3. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH.
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [Abstract] [Full Text] [Related]

  • 4. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
    Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Stockmeyer B, Berens C, Oduncu FS, Mackensen A, Fey GH.
    MAbs; 2012 Jul; 4(1):45-56. PubMed ID: 22327429
    [Abstract] [Full Text] [Related]

  • 5. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.
    Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH.
    Cancer Lett; 2011 Apr 28; 303(2):128-39. PubMed ID: 21339041
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
    Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ, Repp R, Valerius T, Fey GH.
    Br J Haematol; 2004 Apr 28; 125(2):167-79. PubMed ID: 15059139
    [Abstract] [Full Text] [Related]

  • 8. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B.
    J Immunol; 2010 Feb 01; 184(3):1210-7. PubMed ID: 20042573
    [Abstract] [Full Text] [Related]

  • 9. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA.
    MAbs; 2015 Feb 01; 7(3):584-604. PubMed ID: 25875246
    [Abstract] [Full Text] [Related]

  • 10. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
    Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH.
    Br J Haematol; 2010 Sep 01; 150(5):574-86. PubMed ID: 20636437
    [Abstract] [Full Text] [Related]

  • 11. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA.
    Mol Immunol; 2007 Mar 01; 44(8):1935-43. PubMed ID: 17083975
    [Abstract] [Full Text] [Related]

  • 12. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.
    Cancer Res; 2008 Oct 01; 68(19):8049-57. PubMed ID: 18829563
    [Abstract] [Full Text] [Related]

  • 13. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I.
    J Immunother; 2008 Oct 01; 31(8):752-61. PubMed ID: 18779744
    [Abstract] [Full Text] [Related]

  • 14. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
    Schlapschy M, Fogarasi M, Gruber H, Gresch O, Schäfer C, Aguib Y, Skerra A.
    Protein Eng Des Sel; 2009 Mar 01; 22(3):175-88. PubMed ID: 19022801
    [Abstract] [Full Text] [Related]

  • 15. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M, Weth R, Wels WS.
    J Mol Biol; 2005 Mar 11; 346(5):1299-311. PubMed ID: 15713482
    [Abstract] [Full Text] [Related]

  • 16. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
    Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.
    Leukemia; 2013 Jan 11; 27(1):190-201. PubMed ID: 22660187
    [Abstract] [Full Text] [Related]

  • 17. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
    Kipriyanov SM, Cochlovius B, Schäfer HJ, Moldenhauer G, Bähre A, Le Gall F, Knackmuss S, Little M.
    J Immunol; 2002 Jul 01; 169(1):137-44. PubMed ID: 12077238
    [Abstract] [Full Text] [Related]

  • 18. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M.
    J Mol Biol; 1999 Oct 15; 293(1):41-56. PubMed ID: 10512714
    [Abstract] [Full Text] [Related]

  • 19. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
    Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E.
    J Mol Biol; 2010 Jun 11; 399(3):436-49. PubMed ID: 20382161
    [Abstract] [Full Text] [Related]

  • 20. Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.
    Ranft K, Thepen T, Fischer R, Barth S, Stöcker M.
    Cancer Lett; 2009 Sep 18; 282(2):187-94. PubMed ID: 19345477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.